Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Indivior patents

List of Indivior patents

List of Pacific Coast Feather Company patents

List of Rafael Advanced Defense Systems patents

List of Silicon Graphics International patents

List of Hub Ventures Apr 2012 companies

Films directed by Metin Hüseyin

Patents where

Current Assignee

Name

is

Indivior

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 10010612 Sustained delivery formulations of risperidone compounds	Patent 10010612 was granted and assigned to Indivior on July, 2018 by the United States Patent and Trademark Office.		Indivior		United States Patent and Trademark Office	10010612	July 3, 2018
	‌ US Patent 9498432 Injectable flowable composition comprising buprenorphine	Patent 9498432 was granted and assigned to Indivior on November, 2016 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	9498432	November 22, 2016
	‌ US Patent 9272044 Injectable flowable composition buprenorphine	Patent 9272044 was granted and assigned to Indivior on March, 2016 by the United States Patent and Trademark Office.		Indivior		United States Patent and Trademark Office	9272044	March 1, 2016
	‌ US Patent 10058554 Sustained release small molecule drug formulation	Patent 10058554 was granted and assigned to Indivior on August, 2018 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	10058554	August 28, 2018
	‌ US Patent 9295645 Compositions comprising buprenorphine	Patent 9295645 was granted and assigned to Indivior on March, 2016 by the United States Patent and Trademark Office.		Indivior		United States Patent and Trademark Office	9295645	March 29, 2016
	‌ US Patent 9687454 Sublingual and buccal film compositions	Patent 9687454 was granted and assigned to Indivior on June, 2017 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	9687454	June 27, 2017
	‌ US Patent 10000477 Dopamine D3 receptor antagonist compounds	Patent 10000477 was granted and assigned to Indivior on June, 2018 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	10000477	June 19, 2018
	‌ US Patent 10239870 Dopamine D3 receptor antagonists	Patent 10239870 was granted and assigned to Indivior on March, 2019 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	10239870	March 26, 2019
	‌ US Patent 9486531 Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system	Patent 9486531 was granted and assigned to Indivior on November, 2016 by the United States Patent and Trademark Office.		Indivior		United States Patent and Trademark Office	9486531	November 8, 2016
	‌ US Patent 10172849 Compositions comprising buprenorphine	Patent 10172849 was granted and assigned to Indivior on January, 2019 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	10172849	January 8, 2019
	‌ US Patent 9186413 Sustained delivery formulations of risperidone compounds	Patent 9186413 was granted and assigned to Indivior on November, 2015 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	9186413	November 17, 2015
	‌ US Patent 10198218 Injectable flowable composition comprising buprenorphine	Patent 10198218 was granted and assigned to Indivior on February, 2019 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	10198218	February 5, 2019
	‌ US Patent 9180197 Sustained delivery formulations of risperidone compounds	Patent 9180197 was granted and assigned to Indivior on November, 2015 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	9180197	November 10, 2015
	‌ US Patent 10149912 Dehydrated hydrogel inclusion complex	Patent 10149912 was granted and assigned to Indivior on December, 2018 by the United States Patent and Trademark Office.	Indivior	Indivior		United States Patent and Trademark Office	10149912	December 11, 2018
	‌ US Patent 10022367 Sustained-release buprenorphine solutions	Patent 10022367 was granted and assigned to Indivior on July, 2018 by the United States Patent and Trademark Office.		Indivior		United States Patent and Trademark Office	10022367	July 17, 2018

15 results

0 selected

15 results

0 selected